Risk Factors Associated with Linkage to Care among Suburban Hepatitis C-Positive Baby Boomers and Injection Drug Users.

Hepatitis C virus Intravenous drug abuse Linkage to care Risk factors

Journal

Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 01 04 2019
pubmed: 28 5 2019
medline: 28 5 2019
entrez: 27 5 2019
Statut: ppublish

Résumé

Suffolk County, located in Eastern Long Island, has been an epicenter for the opioid epidemic in New York State, yet no studies have examined hepatitis C virus (HCV) prevalence in this population. Additionally, few studies have assessed barriers for linkage to care (LTC) to HCV treatment in people who inject drugs (PWID), a high-risk HCV cohort. We aimed to determine prevalence of HCV infection in a suburban medical center and to assess risk factors associated with LTC in HCV-positive baby boomers and young PWID. A retrospective chart review was carried out on adult patients with ICD-9/10 diagnostic codes for HCV from January 2016 to December 2018 at Stony Brook Medicine. Data collected included sociodemographics, RNA serostatus, LTC, health insurance, employment, past medical or psychiatric history, and substance or injection drug use. Overall, 27,049 individuals were screened for HCV and 1017 were HCV seropositive (3.8%), 437 (42.9%) were HCV RNA-positive and 153 (40.6%) achieved LTC. In multivariate analysis, living with cirrhosis was associated with a positive LTC. Medicaid or Medicare insurance was associated with a negative LTC. Intravenous drug users were more likely to be young and have concomitant polysubstance use and psychiatric disease. A bimodal distribution of HCV-positives is present in our population. Those with liver cirrhosis are more likely to achieve LTC, as are those with private insurance. Public health efforts to promote awareness of HCV and to facilitate access to treatment among PWID are needed.

Identifiants

pubmed: 31129777
doi: 10.1007/s40121-019-0249-y
pii: 10.1007/s40121-019-0249-y
pmc: PMC6702540
doi:

Types de publication

Journal Article

Langues

eng

Pagination

417-428

Références

N Engl J Med. 1999 Aug 19;341(8):556-62
pubmed: 10451460
MMWR Morb Mortal Wkly Rep. 2011 May 6;60(17):537-41
pubmed: 21544042
Liver Int. 2011 Sep;31(8):1090-101
pubmed: 21745274
Am J Public Health. 2013 Jan;103(1):e44-52
pubmed: 23153148
Am J Public Health. 2013 Jan;103(1):112-9
pubmed: 23153151
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
J Infect Dis. 2013 Mar;207 Suppl 1:S1-6
pubmed: 23390299
Clin Infect Dis. 2013 Oct;57(7):1014-20
pubmed: 23728143
Ann Intern Med. 2013 Sep 3;159(5):349-57
pubmed: 23798026
Clin Infect Dis. 2013 Aug;57 Suppl 2:S111-7
pubmed: 23884058
Clin Infect Dis. 2013 Aug;57 Suppl 2:S51-5
pubmed: 23884066
Clin Infect Dis. 2013 Aug;57 Suppl 2:S80-9
pubmed: 23884071
Int J Drug Policy. 2014 Jan;25(1):34-52
pubmed: 23973009
Am J Public Health. 2014 Sep;104(9):1713-21
pubmed: 24134382
BMJ Open. 2014 May 29;4(5):e004988
pubmed: 24875490
Liver Int. 2015 Feb;35(2):489-501
pubmed: 24923487
Clin Infect Dis. 2014 Nov 15;59(10):1411-9
pubmed: 25114031
Open Forum Infect Dis. 2014 May 14;1(1):ofu009
pubmed: 25734083
MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):453-8
pubmed: 25950251
J Hosp Med. 2015 Aug;10(8):510-6
pubmed: 26033458
Ann Emerg Med. 2016 Jan;67(1):119-28
pubmed: 26253712
Am J Public Health. 2016 Feb;106(2):353-8
pubmed: 26562129
Clin Infect Dis. 2016 May 15;62(10):1287-1288
pubmed: 26936668
J Emerg Med. 2016 Jun;50(6):825-831.e2
pubmed: 26954104
Emerg Infect Dis. 2016 May;22(5):907-9
pubmed: 27089172
Public Health Rep. 2016 May-Jun;131 Suppl 2:84-90
pubmed: 27168666
Subst Use Misuse. 2016 Jul 28;51(9):1218-23
pubmed: 27219274
PLoS One. 2016 Aug 15;11(8):e0161241
pubmed: 27525983
Open Forum Infect Dis. 2016 Oct 4;3(4):ofw211
pubmed: 28066793
Clin Infect Dis. 2017 Jun 1;64(11):1540-1546
pubmed: 28207069
Int J Equity Health. 2017 Jun 14;16(1):101
pubmed: 28615023
Int J Drug Policy. 2017 Sep;47:86-94
pubmed: 28648353
Open Forum Infect Dis. 2017 May 27;4(3):ofx109
pubmed: 28752101
Public Health Rep. 2018 Jul/Aug;133(4):497-501
pubmed: 29902392
J Viral Hepat. 2018 Dec;25(12):1438-1445
pubmed: 29974582
JAMA Netw Open. 2018 Dec 7;1(8):e186371
pubmed: 30646319

Auteurs

Audun J Lier (AJ)

Department of Internal Medicine, Stony Brook University Hospital, New York, USA. Audun.Lier@stonybrookmedicine.edu.

Kalie Smith (K)

Division of Infectious Diseases, Department of Internal Medicine, Stony Brook University Hospital, New York, USA.

Kerim Odekon (K)

Department of Internal Medicine, Stony Brook University Hospital, New York, USA.

Silvia Bronson (S)

Division of Infectious Diseases, Department of Internal Medicine, Stony Brook University Hospital, New York, USA.

Erin Taub (E)

Department of Internal Medicine, Stony Brook University Hospital, New York, USA.

Mathew Tharakan (M)

Department of Internal Medicine, Stony Brook University Hospital, New York, USA.

Gerald J Kelly (GJ)

Division of Family and Community Medicine, Department of Family, Population and Preventive Medicine, Stony Brook University Hospital, New York, USA.

Pruthvi Patel (P)

Division of Gastroenterology, Department of Internal Medicine, Stony Brook University Hospital, New York, USA.

Luis A Marcos (LA)

Division of Infectious Diseases, Department of Internal Medicine, Stony Brook University Hospital, New York, USA.

Classifications MeSH